Floatz logo

Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer

Urothelial Carcinoma

Eli Lilly and Companymonoclonal_antibodyPhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

163 Active assets in the Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Beijing Biotech
Phase 3BB
Durvalumab
Alliance for Clinical Trials in Oncology
Phase 3BB
Cis-Diamminedichloroplatinum Ii
Nagoya University
Phase 3BB
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Vasgene Therapeutics, Inc
Phase 2/3BB
Pembrolizumab
Sutro Biopharma, Inc.
Phase 3BB

View all 50 →

Same molecule, other indications

Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer is also rated in:

hepatocellular carcinomaActive
BB
Indicative · Phase 3
65 / 100
View asset →
lung cancerActive
BB
Indicative · Phase 3
64 / 100
View asset →
cancerActive
B
Indicative · Phase 2
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →